40 Years of ME/CFS: What Has Really Changed?
Forty years into the modern history of ME/CFS, where are we—and which questions have we still failed to answer?
The illness has travelled a troubling path: from the dismissive label “yuppie flu,” through decades in which symptoms were frequently attributed to psychological or psychosomatic causes, to the present day, when patients can still encounter physicians who question the nature, severity, or biological basis of their symptoms.
So, after four decades, what has really changed?
There is unquestionably greater scientific interest in the biology of ME/CFS. Researchers are investigating immune abnormalities, metabolism, autonomic dysfunction, neurological changes, the microbiome, viral reactivation, and other potential mechanisms. Yet no single cause has been established, no universally accepted diagnostic biomarker exists, and patients are still frequently told that routine investigations reveal “nothing abnormal.”
But “nothing found” and “nothing there” are not scientifically equivalent statements.
That distinction should matter enormously in an illness in which the relevant pathology may not be continuously present in peripheral blood, may fluctuate over time, or may potentially involve tissues and biological compartments that are rarely examined in routine clinical practice.
After forty years, we therefore need to ask a more uncomfortable question:
Have we investigated ME/CFS comprehensively—or have we repeatedly investigated what is easiest to measure?
Which viruses, bacteria, fungi, or other microorganisms have been adequately investigated, and which have not? Which tissues have actually been examined? At what stages of illness? Using which technologies? And how often have apparently negative findings from blood been interpreted more broadly than the evidence permits?
Have researchers sufficiently investigated persistent or latent infections, viral reactivation, altered viral states, immune dysfunction, microbial interactions, and combinations of infectious and host factors? Or has the search too often been framed around finding one pathogen that behaves according to conventional expectations of acute infection?
What About Enteroviruses?
Enteroviruses deserve particular scrutiny because they have repeatedly appeared in the history of ME/CFS research.
And this leads to another difficult question: what exactly do we mean when we say that a virus is “gone”?
If infectious virus can no longer readily be recovered from blood, does that establish that viral material cannot persist elsewhere? What about tissue reservoirs, persistent viral RNA, defective or altered viral forms, low-level infection, or remnants capable of influencing immune function?
Poliovirus provides a particularly provocative example. Rather than simply asserting that poliovirus can or cannot remain “dormant,” the scientifically relevant question is more precise:
What forms of long-term poliovirus or enterovirus persistence have actually been excluded, in which human tissues, by which methods, and over what period of time?
If long-term persistence is considered biologically implausible, what experimental evidence demonstrates that? Have modern molecular techniques been used to examine the appropriate tissues in carefully characterised patients? And if they have not, how confidently can the hypothesis be dismissed?
Absence from routine blood testing is evidence about blood at the time it was sampled. It should not automatically become evidence of absence from every tissue in the human body.
Which Research Was Abandoned—and Why?
There is another question that deserves considerably more attention:
Which potentially important lines of ME/CFS research were abandoned, rejected, or insufficiently followed up—and what was the scientific justification for doing so?
A hypothesis can fail for many reasons.
The original observation may have been wrong. A laboratory result may have reflected contamination. A statistical association may disappear in a larger study. A proposed pathogen may genuinely have no relationship to the disease.
But replication can also fail because laboratories use different protocols, reagents, primers, specimens, patient-selection criteria, storage conditions, sampling times, tissues, culture methods, or detection thresholds.
Those possibilities are not interchangeable.
Simply stating that a finding “could not be replicated” does not, by itself, explain what was actually replicated, how closely the original methodology was followed, or why the results differed.
That distinction becomes particularly important when examining one of the most controversial episodes in ME/CFS research: the work of Dr. Elaine DeFreitas and colleagues at the Wistar Institute in Philadelphia.
DeFreitas and colleagues reported evidence they interpreted as suggesting an association between ME/CFS and a retrovirus-like agent. Subsequent attempts by other investigators did not consistently reproduce the findings, and the proposed association was ultimately not accepted.
But that should not be the end of the historical inquiry.
The relevant question is not whether we should simply accept the original DeFreitas hypothesis today.
The question is:
Was it conclusively disproven, or did the scientific community stop pursuing it because the available replication attempts failed to confirm it?
Those are not necessarily the same thing.
Her published work, laboratory methodology, associated patent documentation, reported observations, and the subsequent replication attempts should therefore be examined side by side.
What exactly did DeFreitas report?
What biological material was detected?
Which patient populations and controls were examined?
Which tissues or specimens were used?
What laboratory procedures were required?
How closely did subsequent investigators reproduce those procedures?
Where did their methods differ?
And most importantly: could technologies available today answer questions that laboratory methods of the early 1990s could not?
However, "her 91-page patent literature and papers detailing the full virus isolation procedure".
The John Martin Findings
Similar scrutiny should be applied to the work of Dr. John Martin and others who reported unusual viral or virus-like findings in patients with chronic illnesses.
Again, the purpose should not be to declare decades-old hypotheses correct simply because they were controversial or subsequently neglected.
The purpose should be to determine exactly what was observed, what was independently reproduced, what was not reproduced, and what remains unresolved.
If virus-isolation findings were reported, what became of the original isolates?
Were they independently characterised?
Were specimens preserved?
Could archived material still exist?
Were electron micrographs independently evaluated?
Could genomic sequencing, metagenomic sequencing, proteomics, modern electron microscopy, single-cell analysis, spatial transcriptomics, or other contemporary techniques now determine what earlier researchers were observing?
If the answer is that the original findings were artefacts, contamination, or misidentification, then modern investigation should be capable of demonstrating that convincingly.
But if nobody has returned to the original biological material with modern tools, then the more accurate description may be unresolved, rather than simply irrelevant.
Replication Must Work in Both Directions
Scientific scepticism is essential. Extraordinary claims require strong evidence.
But scepticism must operate in both directions.
Researchers proposing an infectious cause must provide reproducible evidence.
Researchers rejecting that possibility should likewise be able to demonstrate that the relevant hypothesis was adequately tested.
A failed replication is important evidence. But it should trigger another question:
Why did replication fail?
Were the same patient populations studied?
Were patients at comparable stages of illness?
Were identical specimens collected?
Were the same tissues investigated?
Were samples collected and stored in comparable ways?
Were the same reagents, primers, culture conditions, and detection thresholds used?
Was the biological target expected to be continuously present in blood?
And was the attempted replication actually capable of detecting what the original researchers claimed to have found?
These are not arguments against scientific replication.
They are arguments for more rigorous replication.
Forty Years Later, We Have Better Tools
Science today possesses capabilities that researchers investigating ME/CFS in the 1980s and 1990s could scarcely have imagined.
We now have high-throughput sequencing, metagenomics, single-cell technologies, advanced proteomics and metabolomics, improved imaging, sophisticated immunological profiling, computational analysis, and increasingly powerful methods for examining biological material within specific tissues.
That creates an opportunity—and perhaps an obligation—to revisit important unresolved observations from the history of ME/CFS.
Not because the earlier researchers must have been right.
And not because every abandoned hypothesis deserves resurrection.
But because “we did not confirm it thirty years ago” is not necessarily the same scientific conclusion as “modern evidence demonstrates that it cannot be true.”
ME/CFS patients have already waited decades.
They deserve research that is willing not only to pursue fashionable new hypotheses, but also to examine whether potentially important questions were prematurely closed.
After forty years, perhaps we need to stop asking only:
“What have we found?”
We should also be asking:
“What have we failed to find because we looked in the wrong place, at the wrong time, or with the wrong tools?”
And perhaps the most uncomfortable question of all:
“What—and where—did we stop looking, why did we stop, and was the evidence truly sufficient to justify stopping?”
Comments
Post a Comment